Equities analysts predict that Kadmon Holdings, Inc. (NASDAQ:KDMN) will report sales of $420,000.00 for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Kadmon’s earnings, with the lowest sales estimate coming in at $190,000.00 and the highest estimate coming in at $710,000.00. Kadmon reported sales of $490,000.00 during the same quarter last year, which would suggest a negative year-over-year growth rate of 14.3%. The firm is expected to announce its next quarterly earnings results on Thursday, November 4th.
According to Zacks, analysts expect that Kadmon will report full year sales of $5.17 million for the current fiscal year, with estimates ranging from $3.94 million to $7.20 million. For the next financial year, analysts anticipate that the firm will report sales of $56.96 million, with estimates ranging from $27.18 million to $71.34 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that follow Kadmon.
Kadmon (NASDAQ:KDMN) last issued its quarterly earnings results on Thursday, August 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.18). The firm had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.34 million. Kadmon had a negative return on equity of 260.49% and a negative net margin of 5,961.77%.
Shares of KDMN traded up $0.09 during trading hours on Friday, reaching $8.89. 38,457 shares of the company’s stock traded hands, compared to its average volume of 4,705,883. The firm’s 50 day simple moving average is $5.54 and its 200-day simple moving average is $4.50. The stock has a market cap of $1.53 billion, a PE ratio of -13.13 and a beta of 1.63. Kadmon has a 12 month low of $3.14 and a 12 month high of $9.20. The company has a current ratio of 9.46, a quick ratio of 9.46 and a debt-to-equity ratio of 16.51.
Large investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD boosted its stake in shares of Kadmon by 20.7% in the second quarter. Price T Rowe Associates Inc. MD now owns 14,173 shares of the company’s stock worth $55,000 after acquiring an additional 2,427 shares during the last quarter. Teacher Retirement System of Texas lifted its stake in Kadmon by 18.2% in the second quarter. Teacher Retirement System of Texas now owns 16,395 shares of the company’s stock worth $63,000 after acquiring an additional 2,519 shares during the last quarter. Parametric Portfolio Associates LLC lifted its position in shares of Kadmon by 2.4% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 120,448 shares of the company’s stock worth $466,000 after buying an additional 2,834 shares during the last quarter. Swiss National Bank increased its stake in Kadmon by 1.3% in the 1st quarter. Swiss National Bank now owns 293,900 shares of the company’s stock valued at $1,143,000 after buying an additional 3,700 shares during the period. Finally, Amalgamated Bank boosted its stake in shares of Kadmon by 21.5% during the 2nd quarter. Amalgamated Bank now owns 32,732 shares of the company’s stock worth $127,000 after acquiring an additional 5,795 shares in the last quarter. Hedge funds and other institutional investors own 95.79% of the company’s stock.
Kadmon Holdings, Inc is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company’s clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases.
Featured Article: How Investors Can Profit from Options Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.